ICER report undervalues abuse-deterrent opioids, physician group says

A draft report on abuse-deterrent opioids understates their value, according to the Institute for Patient Access (IfPA).

Abuse-deterrent formulations (ADFs) allow manufacturers to create opioid medications that resist crushing or dissolving for recreational use, helping to curb the abuse which has become both widespread and highly damaging across the USA, but without impeding access for patients who use these medications appropriately to manage pain.

The Institute for Clinical and Economic Review, (ICER), an independent US not-for-profit organization, gave the IfPA, a physician-led policy research organization, the chance to provide feedback on its draft report evaluating the effectiveness and value of ADFs.